Journal of Clinical Engineering

Nighswonger, Gregg; Brush, Linnea C.; Kiser, Brenda H.; Knepher, Michael S.; Norwood, Tina D.; Morales, Krystal M.; Waltham, Mary

doi:10.1097/00004669-199505000-00001

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of DCC-3014 and the murine anti-PD1 antibody in the MC38 colorectal cancer model showed an improvement in the inhibitory effect and a synergistic immunomodulatory activity by the added blocking of macrophage immune checkpoints compared with other treatment alone . DCC-3014 is currently in phase I clinical trials in patients with advanced malignancies to assess its safety, PK, and PD using different doses. − …”

Section: Csf-1r Kinase Inhibitorsmentioning

confidence: 99%

Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors

et al. 2018

View full text Add to dashboard Cite

Colony stimulation factor-1 receptor (CSF-1R), which is also known as FMS kinase, plays an important role in initiating inflammatory, cancer, and bone disorders when it is overstimulated by its ligand, CSF-1. Innate immunity, as well as macrophage differentiation and survival, are regulated by the stimulation of the CSF-1R. Another ligand, interlukin-34 (IL-34), was recently reported to activate the CSF-1R receptor in a different manner. The relationship between CSF-1R and microglia has been reviewed. Both CSF-1 antibodies and small molecule CSF-1R kinase inhibitors have now been tested in animal models and in humans. In this Perspective, we discuss the role of CSF-1 and IL-34 in producing cancer, bone disorders, and inflammation. We also review the newly discovered and improved small molecule kinase inhibitors and monoclonal antibodies that have shown potent activity toward CSF-1R, reported from 2012 until 2017.

show abstract

Section: Csf-1r Kinase Inhibitorsmentioning

confidence: 99%